Advertisement
NIOXIN(R) has entered into an agreement with HairDX, a biotech start-upbased in Irvine, CA, to offer the test as part of its next generation effortin introducing scientifically proven scalp and hair products. HairDX is thefirst genome test to be made available to consumers in helping assess theirrisk and genetic predisposition for developing pattern baldness (AndrogeneticAlopecia). This new genetic test is accessible through the internet atwww.nioxin.com and will be promoted at consumer education events heldnationally beginning March 1st 2008.
Advertisement
According to the American Hair Loss Association, by the age of 35,two-thirds of American men will experience some degree of appreciable hairloss and by the age of 50, approximately 85% of men will have significantlythinning hair.
"Gaining a better understanding of the potential cause of an individual'scondition enables a more accurate assessment of the most appropriatesolution," said Eva Graham, founder of NIOXIN(R) Research Laboratories, Inc.
"HairDX is proud to work with NIOXIN(R) to help genetic science make apositive contribution to scalp and hair care," said Andy Goren, CEO of HairDX."This provides a personalized profile for many individuals who can benefitfrom knowing their risk of hair loss and allow them to take action early,before the condition becomes severe."
HOW IT WORKS:
The participant simply swabs their mouth (inside cheek) for severalseconds and returns the swab in a sealed pack to the HairDX lab. HairDXperforms a confidential and anonymous genetic analysis of the individual'sgenetic variations related to pattern baldness. The confidential results aredelivered via a secure Web site.
"HairDX tests for a genetic variant found in more than 95% of bald men.60% of patients with this variant experienced male pattern baldness before theage of 40, thus it is a marker for a significant increased risk of patternbaldness," says Professor Doron Lancet, PhD, a pioneer of genome research andHead of the Crown Human Genome Center at the Department of Molecular Genetics,Weizmann Institute of Science in Rehovot, Israel. "This is in contrast to theless common genetic variant of the same gene, present in about 1 in 6 people,which indicates greater than 85% likelihood that a person will not experienceearly onset pattern baldness."
About HairDX
Based in Irvine, CA, HairDX was founded by leading researchers andspecialists in genetic analysis and hair therapies. The company is dedicatedto helping people make the right decisions about hair care, treatment andrestoration by providing accurate and accessible personalized scientificinformation.
Among HairDX founders is William V. Murray former Division President ofthe Molecular Biology Division of Applied BioSystems, Inc., who formerlyserved in various executive leadership positions within Medtronic; Andy Gorenformer CEO of MobileWise, Inc. and GeePS, Inc.; Eran Goren, CEO of enCircleMedia, Inc.; Professor Doron Lancet, PhD, Head of the Crown Human GenomeCenter at the Department of Molecular Genetics, Weizmann Institute of Science;Dr. Peter Novak, a Neurologist at the University of Massachusetts MedicalCenter; Elliott J. Stein, an intellectual property attorney and co-founder ofGeePS, Inc. and Mace Wolf. HairDX, LLC is a subsidiary of myGenopedia, Inc.More information is available at www.hairdx.com.
About NIOXIN Research Laboratories Inc.
NIOXIN(R) is the leading provider of advanced skincare solutions thattreat the scalp to imp
